Topicals: local action without psychoactive effect

TL;DR

• Act on CB2 receptors on keratinocytes and skin immune cells.
• No or minimal systemic THC (Paudel 2010).
• Common uses: muscle tension, minor joint discomfort, eczema symptoms.
• Transdermal patches are the exception – systemic absorption is possible.

Why topicals don't get you high

The stratum corneum is a lipophilic barrier. Cannabinoids stay in the epidermis and engage the cutaneous ECS – without meaningful blood levels.

Topical application: local instead of systemic

Creams, balms, and ointments with cannabinoids act via CB2 receptors and other target structures in the skin, subcutis, and peripheral nerve endings. Crucial for understanding: under normal use, cannabinoids practically do not reach the bloodstream in relevant quantities. There is no intoxicating effect, and a drug test will as a rule not trigger from a CBD cream.

The formulation determines absorption through the stratum corneum. Lipophilic bases, liposomes, or penetration enhancers improve transport; a water-based gel with added CBD, on the other hand, remains largely on the surface. Transdermal patches are a special case: they are explicitly designed to deliver the active ingredient systemically, and thus behave differently from classic topicals.

• No intoxicating effect, virtually no systemic absorption
• Formulation and base determine skin permeability
• Transdermal patches deliberately act systemically — different risk profile
• Do not apply to open wounds and irritated skin

Cosmetics law and realistic expectations

In Switzerland, topical cannabinoid products mostly fall under cosmetics law. Consequently, skincare claims are permitted, but therapeutic claims are not — this would require Swissmedic approval as a medicinal product. The available evidence on topical CBD comes predominantly from small studies and observational trials; it justifies a trial for local complaints, but does not replace a medical assessment. Before large-scale application, a patch test on a small area of skin is recommended.

Swiss classification: Products with less than 1% total THC (THC + THCA × 0.877) are not narcotics and are freely available; above this, the Narcotics Act applies. For road traffic, the method of consumption is irrelevant — the decisive factor is the detection limit value of 1.5 µg THC per litre of blood, which leads to unfitness to drive. Medical cannabis has been prescribable by doctors without an exceptional permit from the BAG since August 2022.

Galenic differences: comparing ointment, cream, and gel

The choice of the right carrier medium is crucial for the release of cannabinoids into the skin layers. Anhydrous ointments and rich balms are mostly based on vegetable oils, beeswax, or fatty alcohols. These lipophilic bases form an occlusive film on the epidermis, which reduces transepidermal water loss and causes the stratum corneum to swell. This allows lipophilic active ingredients such as CBD or THC to penetrate more easily into the deeper layers of the epidermis. Such formulations are particularly suitable for very dry, flaky skin areas or for targeted massage of stressed muscle groups.

In contrast, there are light emulsions such as creams and hydrophilic gels. Creams contain both water and oil phases stabilized by emulsifiers, allowing them to absorb more quickly without leaving a lasting greasy film. Water-based gels primarily have a cooling effect, but without special penetration enhancers, they have a lower depth of action for cannabinoids. For daily skincare or large-scale applications, light creams are therefore usually preferred, while gels with additional plant extracts are used for acute, cooling effects. The galenic formulation thus significantly determines the area of application.

• Ointments and balms act occlusively and promote the penetration of lipophilic cannabinoids.
• Creams offer a compromise between rapid absorption and nourishing properties.
• Hydrogels have a cooling effect but often require excipients for deeper penetration of the active ingredient.
• The choice of base should always be tailored to the individual skin type.

Risks, allergenic potential, and dermatological safety

Although topical cannabis products are considered highly tolerable, excipients in the formulations can cause adverse skin reactions. Cannabinoid extracts naturally contain a variety of terpenes, which can act as contact allergens in sensitive individuals. In addition, essential oils such as menthol, camphor, or arnica are frequently added to commercial products to enhance the cooling or warming effect. These additives carry a higher risk of contact dermatitis or skin irritation than the cannabinoids themselves. Therefore, a patch test in the crook of the elbow is advisable before widespread application.

Another risk concerns application to damaged skin barriers. In the case of eczema, open wounds, or severe inflammation, the protective function of the stratum corneum is severely compromised. In these cases, ingredients can penetrate deeper into the tissue and unexpectedly enter the systemic bloodstream or promote local infections. Consumers should ensure that products are free from synthetic fragrances, parabens, and mineral oils to minimize the potential for irritation. In the event of persistent skin problems, professional dermatological advice should always be sought before use.

• Terpenes and essential additives can trigger contact allergies in sensitive skin.
• A simple self-test in the crook of the elbow minimizes the risk of widespread reactions.
• Cosmetics must not be applied to damaged skin or open wounds.
• Synthetic preservatives and fragrances increase the potential for skin irritation.

Swiss market surveillance and quality standards

In Switzerland, cannabis topicals are subject to strict official control by the cantonal laboratories and the Federal Food Safety and Veterinary Office (BLV). Since most of these products are classified as cosmetics, they must comply with the requirements of the Ordinance on Cosmetic Products. This means, among other things, that manufacturers must demonstrate the safety of the product by means of a safety report. Furthermore, cosmetics must not carry any health-related or therapeutic claims. Compliance with these advertising bans is regularly monitored and sanctioned by the cantonal enforcement authorities.

For consumers in Switzerland, this regulation offers a high degree of safety regarding ingredients. Swiss products are often characterised by seamless traceability of raw materials. Since the limit for the total THC content is below one percent, manufacturers must be able to present precise analyses to avoid classification as an illegal narcotic. When purchasing, attention should therefore be paid to certified Swiss laboratory tests that prove the exact cannabinoid content as well as the absence of pesticides, heavy metals, and microbiological contaminants.

• Cantonal laboratories monitor compliance with the Swiss Cosmetics Ordinance.
• Therapeutic claims are strictly prohibited for cosmetic cannabis topicals in Switzerland.
• The total THC content must strictly remain below the statutory limit of one percent.
• Independent laboratory analyses ensure purity from heavy metals and pesticide residues.

Magistral formulas: Medical ointments from the pharmacy

In addition to over-the-counter cosmetics, it is possible in Switzerland to have high-dose or specifically tailored cannabis topicals prepared as a magistral formula in a pharmacy. Since the amendment to the law in August 2022, doctors can prescribe medical cannabis preparations directly on a regular prescription, without requiring an exceptional authorisation from the BAG. These individual formulas are prepared by specialised pharmacies under strict Good Manufacturing Practice (GMP) guidelines. They often contain standardised active ingredient concentrations of THC and CBD, tailored exactly to the therapeutic needs of the patient.

The decisive advantage of these medical topicals lies in their pharmaceutical quality and medical supervision. While cosmetics primarily serve skincare purposes, magistral formulas are intended for the treatment of specific ailments such as chronic pain conditions or severe dermatological diseases. Under certain conditions and subject to prior cost coverage approval, the costs of such medically prescribed formulas are covered by health insurance. This represents an important distinction from the grey market, where consumers must always bear the costs of skincare products themselves.

• Magistral formulas are prepared individually in Swiss pharmacies under GMP conditions.
• Since August 2022, direct prescription has been possible without a BAG exceptional authorisation.
• Medical ointments can feature standardised and higher active ingredient concentrations.
• Reimbursement by health insurance is possible following a case-by-case assessment.

FAQ